文献检索

查找使用阿拉丁产品的科研文献

检索与阿拉丁产品相关的同行评审论文、DOI、PubMed 编号、期刊、作者、CAS 号及研究领域。

科研影响力快照

与阿拉丁产品相关的已发表科研成果

在搜索之前,这些指标可帮助访客快速了解产品关联科研的规模与质量。

346,364+ SCI 论文 与阿拉丁产品引用相关
2,295,288.15 总影响因子 匹配文献记录中影响因子的总和
81.20 最高期刊影响因子 匹配期刊中的最高 IF
6.63 平均期刊影响因子 匹配文献的平均 IF

参考指标 指标基于阿拉丁文献引用数据库及期刊影响因子记录。文献关联仅供科研参考,请以原始文献为准。

热门产品

视图 列表 网格

2 项

设置提升方向
HTR2B
Acta Pharmaceutica Sinica B · 2023 · IF 14.5

Dissecting the novel abilities of aripiprazole: The generation of anti-colorectal cancer effects by targeting Gαq via HTR2B

Haowei Liu,Qiuming Huang,Yunqi Fan,Bo Li,Xuemei Liu,Changhua Hu

Colorectal cancer (CRC) is a type of malignant tumor that seriously threatens human health and life, and its treatment has always been a difficulty and hotspot in research. Herein, this study for the first time reports that antipsychotic aripiprazole (Ari) against the proliferation of CRC cells both in vitro and in vivo , but with less damage in normal colon cells. Mechanistically, the results showed that 5-hydroxytryptamine 2B receptor (HTR2B) and its coupling protein G protein subunit alpha q (G α q) were highly distributed in CRC cells. Ari had a strong affinity with HTR2B and inhibited HTR2B downstream signaling. Blockade of HTR2B signaling suppressed the growth of CRC cells, but HTR2B was not found to have independent anticancer activity. Interestingly, the binding of G α q to HTR2B was decreased after Ari treatment. Knockdown of G α q not only restricted CRC cell growth, but also directly affected the anti-CRC efficacy of Ari. Moreover, an interaction between Ari and G α q was found in that the mutation at amino acid 190 of G α q reduced the efficacy of Ari. Thus, these results confirm that G α q coupled to HTR2B was a potential target of Ari in mediating CRC proliferation. Collectively, this study provides a novel effective strategy for CRC therapy and favorable evidence for promoting Ari as an anticancer agent.

CAS / MDL: 839712-12-8
研究领域: 肿瘤学 · 药理学 · 细胞生物学
✓ 已验证 产品关联 DOI PubMed 高影响因子
查看原文 查看 PubMed
Frontiers in Pharmacology · 2024 · IF 4.4

Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites

Chen Dongliang,Wang Yuanfei,Yang Jianmei,Ou Wanyi,Lin Guiru,Zeng Ze,Lu Xiaomin,Chen Zumin,Zou Lili,Tian Yaling,Wu Aiping,Keating Shelley,Yang Qinhe,Lin Chenli,Liang Yinji

The prevalence of non-alcoholic fatty liver disease (NAFLD) and related mortality are increasing at an unprecedented rate. Traditional Chinese medicine (TCM) has been shown to offer potential for early prevention and treatment for NAFLD. This study examined the new mechanism of "Shenling Baizhu San" (SLBZS) in the prevention and treatment of NAFLD at the preclinical level.The male C57BL/6J mice were randomly divided into three groups: ND (normal diet), WDC (Western Diet+CCl4 injection) and WDC+SLBZS (SLBZS intervention). Body weight, energy intake, liver enzymes, pro-inflammatory factors and steatosis were recorded in detail. Meanwhile, TPH1, 5-HT, HTR2A and HTR2B were tested by qRT-PCR or ELISA. Dynamic changes in gut microbiota and metabolites were further detected through 16S rRNA gene and untargeted metabolomics.

研究领域: 药理学 · 胃肠病学 · 微生物学 · 代谢组学 · 中医
✓ 已验证 DOI 高影响因子
查看原文 查看 PubMed
已复制

文献关联基于可获得的产品、CAS、DOI 及引用记录。收录不代表作者或出版方对阿拉丁产品的背书,请以原始文献为准。